Compare Stocks: ATNM, HUMA, TNXP, and RNA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$1.10 +1.9%	$1.07	$0.74 ▼ $1.74	$34.59M	0.26	146,115 shs	105,763 shs
HUMA Humacyte	$0.41 -9.3%	$0.60	$0.39 ▼ $1.90	$112.59M	2.44	4.10 million shs	8.58 million shs
RNA Avidity Biosciences	$8.40 +1.7%	$11.12	$7.63 ▼ $16.77	$143.69M	N/A	384,311 shs	208,346 shs
TNXP Tonix Pharmaceuticals	$7.30 +0.3%	$11.48	$7.09 ▼ $22.38	$125.20M	1.78	678,389 shs	960,892 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	0.00%	-5.98%	-16.03%	+18.28%	-28.57%
HUMA Humacyte	0.00%	-22.28%	-28.53%	-41.57%	-76.02%
RNA Avidity Biosciences	0.00%	+7.14%	-18.84%	-32.58%	-82.59%
TNXP Tonix Pharmaceuticals	0.00%	-18.07%	-40.55%	-41.74%	-67.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATNM Actinium Pharmaceuticals	$1.10 +1.9%	$1.07	$0.74 ▼ $1.74	$34.59M	0.26	146,115 shs	105,763 shs
HUMA Humacyte	$0.41 -9.3%	$0.60	$0.39 ▼ $1.90	$112.59M	2.44	4.10 million shs	8.58 million shs
RNA Avidity Biosciences	$8.40 +1.7%	$11.12	$7.63 ▼ $16.77	$143.69M	N/A	384,311 shs	208,346 shs
TNXP Tonix Pharmaceuticals	$7.30 +0.3%	$11.48	$7.09 ▼ $22.38	$125.20M	1.78	678,389 shs	960,892 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATNM Actinium Pharmaceuticals	0.00%	-5.98%	-16.03%	+18.28%	-28.57%
HUMA Humacyte	0.00%	-22.28%	-28.53%	-41.57%	-76.02%
RNA Avidity Biosciences	0.00%	+7.14%	-18.84%	-32.58%	-82.59%
TNXP Tonix Pharmaceuticals	0.00%	-18.07%	-40.55%	-41.74%	-67.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATNM Actinium Pharmaceuticals	3.00	Buy	$5.00	354.55% Upside
HUMA Humacyte	2.63	Moderate Buy	$5.68	1,301.08% Upside
RNA Avidity Biosciences	2.25	Hold	$63.75	658.93% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$24.50	235.62% Upside

Current Analyst Ratings Breakdown

Latest ATNM, HUMA, TNXP, and RNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/7/2026	HUMA Humacyte	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
10/6/2026	HUMA Humacyte	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight ➝ Equal Weight	$0.50
10/2/2026	HUMA Humacyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/14/2026	RNA Avidity Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
8/13/2026	HUMA Humacyte	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Speculative Buy	$2.00 ➝ $1.00
8/12/2026	HUMA Humacyte	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.00
8/10/2026	TNXP Tonix Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$27.00
8/6/2026	RNA Avidity Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$25.00
8/3/2026	RNA Avidity Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E-) ➝ Sell (E)
7/28/2026	TNXP Tonix Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	HUMA Humacyte	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$2.00

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATNM Actinium Pharmaceuticals	$35.09M	0.99	N/A	N/A	$1.31 per share	0.84
HUMA Humacyte	$2.04M	55.19	N/A	N/A	$0.02 per share	20.27
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	$13.11M	9.55	N/A	N/A	$19.17 per share	0.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATNM Actinium Pharmaceuticals	-$48.82M	$0.36	N/A	N/A	N/A	N/A	-100.85%	-47.89%	N/A
HUMA Humacyte	-$40.83M	-$0.49	N/A	N/A	N/A	-4,556.29%	-983.32%	-88.84%	11/11/2026 (Estimated)
RNA Avidity Biosciences	N/A	-$2.15	N/A	N/A	N/A	N/A	N/A	N/A	11/12/2026 (Estimated)
TNXP Tonix Pharmaceuticals	-$124.02M	-$12.94	N/A	N/A	N/A	-548.64%	-68.99%	-61.31%	11/9/2026 (Estimated)

Latest ATNM, HUMA, TNXP, and RNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	RNA Avidity Biosciences	-$1.42	-$1.18	+$0.24	-$1.18	$0.67 million	$3.00 million
8/12/2026	Q2 2026	HUMA Humacyte	-$0.1134	-$0.16	-$0.0466	-$0.16	$1.04 million	$0.41 million
8/10/2026	Q2 2026	TNXP Tonix Pharmaceuticals	-$2.64	-$2.44	+$0.20	-$2.44	$7.72 million	$13.54 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATNM Actinium Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATNM Actinium Pharmaceuticals	N/A	10.25	10.25
HUMA Humacyte	2.07	6.21	5.74
RNA Avidity Biosciences	N/A	8.73	8.73
TNXP Tonix Pharmaceuticals	N/A	6.61	6.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATNM Actinium Pharmaceuticals	27.50%
HUMA Humacyte	44.71%
RNA Avidity Biosciences	N/A
TNXP Tonix Pharmaceuticals	82.26%

Insider Ownership

Company	Insider Ownership
ATNM Actinium Pharmaceuticals	0.60%
HUMA Humacyte	3.10%
RNA Avidity Biosciences	3.83%
TNXP Tonix Pharmaceuticals	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATNM Actinium Pharmaceuticals	25	31.44 million	29.32 million	Optionable
HUMA Humacyte	184	277.80 million	269.19 million	Optionable
RNA Avidity Biosciences	190	17.11 million	16.45 million	Optionable
TNXP Tonix Pharmaceuticals	142	17.15 million	16.81 million	Not Optionable

ATNM, HUMA, TNXP, and RNA Headlines

Recent News About These Companies

Analyzing Tonix Pharmaceuticals (NASDAQ:TNXP) and WAVE Life Sciences (NASDAQ:WVE)

October 7, 2026 | americanbankingnews.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded at Wall Street Zen

October 4, 2026 | americanbankingnews.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Rating Raised to "Hold" at Wall Street Zen

October 4, 2026 | marketbeat.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Downgraded by Wall Street Zen to Sell

September 26, 2026 | marketbeat.com

Tonix Pharmaceuticals Holding Corp (TNXP)

September 23, 2026 | in.investing.com

InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Expands TONMYA(R) Medicare Coverage to 32 Million Lives

September 22, 2026 | financialcontent.comF

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

September 22, 2026 | finance.yahoo.com

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®

September 22, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Butterfly Network (BFLY), Tonix Pharma (TNXP) and Solventum Corporation (SOLV)

September 16, 2026 | theglobeandmail.com

Tonix Pharmaceuticals Holding Corp. (TNXP)

September 15, 2026 | finance.yahoo.com

Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears

September 11, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Tonix Pharma (TNXP), Tyra Bioscience (TYRA) and Becton Dickinson (BDX)

September 9, 2026 | theglobeandmail.com

Tonix Names Englese Chief Commercial Officer To Expand TONMYA Reach

September 9, 2026 | rttnews.com

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

September 8, 2026 | finance.yahoo.com

Tonix Pharma Appoints New Chief Commercial Officer

September 8, 2026 | tipranks.com

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer

September 8, 2026 | globenewswire.com

TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26

September 2, 2026 | finance.yahoo.com

Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference

September 2, 2026 | finance.yahoo.com

Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference

September 2, 2026 | globenewswire.com

Insider Buying: Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Acquires 2,000 Shares

September 1, 2026 | insidertrades.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Director Richard Bagger Acquires 1,000 Shares

August 25, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ATNM, HUMA, TNXP, and RNA Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

$1.10 +0.02 (+1.85%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.10 0.00 (-0.09%)

As of 10/9/2026 07:30 PM Eastern

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Humacyte NASDAQ:HUMA

$0.41 -0.04 (-9.35%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.42 +0.01 (+3.38%)

As of 10/9/2026 07:55 PM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Avidity Biosciences NASDAQ:RNA

$8.40 +0.14 (+1.69%)

As of 10/9/2026 04:00 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Tonix Pharmaceuticals NASDAQ:TNXP

$7.30 +0.02 (+0.27%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$7.31 +0.01 (+0.14%)

As of 10/9/2026 07:59 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATNM, HUMA, TNXP, and RNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATNM, HUMA, TNXP, and RNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATNM, HUMA, TNXP, and RNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ATNM, HUMA, TNXP, and RNA Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

Humacyte NASDAQ:HUMA

Avidity Biosciences NASDAQ:RNA

Tonix Pharmaceuticals NASDAQ:TNXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATNM, HUMA, TNXP, and RNA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATNM, HUMA, TNXP, and RNA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATNM, HUMA, TNXP, and RNA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ATNM, HUMA, TNXP, and RNA Company Descriptions

Actinium Pharmaceuticals NYSE:ATNM

Humacyte NASDAQ:HUMA

Avidity Biosciences NASDAQ:RNA

Tonix Pharmaceuticals NASDAQ:TNXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools